Vertex Pharmaceuticals shares (NASDAQ: VRTX) are sat a potentially pivotal support level ahead of today’s earnings report, with the after market print likely to set off a break out of recent range in either direction. The company heads into the print with the stock price up 5.52% YTD, and holding ground on a TTM basis, up 1%.
Expectations for the print are for single digit growth, with the Street looking for EPS of $4.75 on revenue of $3.22 billion. That would reflect a 5% EPS increase Y/Y, with revenue growth of 8.72% from the prior period. The financial year is expected to dip into the low double digits, with 10% sales growth, and EPS (FY27 $21.34) an 11% increase.
Vertex has delivered consistent growth through its cystic fibrosis franchise and has built a track record of pipeline execution. Zooming out, the VRTX has added 137% over the past five years to sit among the stronger performers in the US biotechnology sector.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The AbCellera partnership, announced just days before the earnings date, adds a new dimension to Vertex’s pipeline narrative. The collaboration focuses on multispecific T-cell engagers, a therapeutic modality gaining traction in autoimmune disease research.
What To Watch
Cystic fibrosis revenue performance is likely to take the lead, whilst pipeline progress and guidance will also be closely followed. The AbCellera collaboration signals Vertex’s intent to broaden its therapeutic reach into autoimmune and potentially oncology indications.
Analyst sentiment heading into the print has tilted modestly positive, with upward EPS revisions over the past month. However, the stock’s recent 90-day rally means expectations are elevated, and any shortfall on key metrics could prompt profit-taking.
Options markets are pricing a move in VRTX of ~5.5% following the print, potentially retesting the YTD break even line, or proving a break of $500 depending on direction.
